Clinical Observation of Spironolactane in Treating Chronic Heart Failure

Objective To observe the clinical effects and safety of aldosterone receptors antagonist spironolactone in adjunctive treatment of the chronic heart failure(CHF).Methods 90 patients with chronic heart failure were randomly divided into Spironolactone group(45 cases) and conventional therapy group(45 cases).The two groups were given conventional anti-CHF therapy,the Spironolactone group was given extra 20 mg of Spironolactone twice a day during the same time.6 months after therapy the clinical effect between the two groups,and the biochemical indicator and echocardiography before and after treatment were compared.Results After treatment,the heart function improved in the two groups,and total effectness rate of Spironolactone group was 91.1%.It had statistical significance compared with that of 75.6% of the conventional therapy group(P 0.05).K + was significantly increased after treatment in Spironolactone group compared with that before treatment,and the result showed statistical significance(P 0.05).But there was no significant difference in conventional therapy group before and after treatment,and the result showed no statistical significance(P 0.05).After treatment,K + of the two groups were campared with statistical significance(P 0.05).After treatment,BP,CO,LVEDV,LVESV and LVEF of the patients in the Spironolactone group were significantly improved,with significant difference from that of the conventional therapy group(P 0.05). Conclusion On the basis of conventional anti-CHF threapy,administration of extra Spironolactone is effective and safe,can significantly improve the heart function of patients with CHF,inhibit ventricular remodeling and delay the deterioration of the disease.